Work

Table S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Year: 2023

Type: other

Abstract: A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group being CTC 0.

DOI: 10.1158/1078-0432.22820161

Authors: Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, David M. Nanus, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Richard Wenstrup, Andrew J. Armstrong

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4376611133

Cites:

Cited by:

Related to: 8